A selective angiotensin receptor antagonist , Valsartan , produced <font color="red">regression_2</font> <font color="red">of_1</font> <font color="red">left_1</font> <font color="red">ventricular_1</font> <font color="red">hypertrophy_1</font> associated with a <font color="red">reduction_1</font> <font color="red">of_1</font> <font color="red">arterial_2</font> <font color="red">stiffness_2</font> <font color="red">._2</font> 
<br>
<br> We investigated whether a selective angiotensin II receptor blocker ( ARB ) would have a <font color="red">regressive_2</font> <font color="red">effect_2</font> <font color="red">on_1</font> <font color="red">left_1</font> <font color="red">ventricular_1</font> <font color="red">hypertrophy_1</font> <font color="red">(_1</font> <font color="red">LVH_1</font> <font color="red">)_1</font> in patients on continuous ambulatory peritoneal dialysis ( CAPD ) . In a double - blind study , 24 CAPD patients with <font color="red">LVH_1</font> <font color="red">[_1</font> <font color="red">left_1</font> <font color="red">ventricular_1</font> <font color="red">mass_1</font> <font color="red">index_1</font> <font color="red">(_1</font> <font color="red">LVMi_1</font> <font color="red">)_1</font> <font color="red">>_1</font> <font color="red">110_1</font> <font color="red">g_1</font> <font color="red">/_1</font> <font color="red">m2_1</font> <font color="red">for_1</font> <font color="red">women_1</font> and <font color="red">LVMi_1</font> <font color="red">>_1</font> <font color="red">137_1</font> <font color="red">g_1</font> <font color="red">/_1</font> <font color="red">m2_1</font> <font color="red">for_1</font> <font color="red">men_1</font> <font color="red">]_1</font> were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a placebo ( n = 10 ) . The <font color="red">target_1</font> <font color="red">blood_2</font> <font color="red">pressure_2</font> <font color="red">(_2</font> <font color="red">BP_2</font> <font color="red">)_2</font> <font color="red">was_1</font> <font color="red">140/90_1</font> <font color="red">mmHg_1</font> <font color="red">or_1</font> <font color="red">lower_1</font> in both groups . The following parameters were measured before and at the end of the study : <font color="red">aortic_2</font> <font color="red">and_2</font> <font color="red">large_2</font> <font color="red">-_2</font> <font color="red">artery_2</font> <font color="red">compliance_2</font> <font color="red">and_1</font> <font color="red">arterial_2</font> <font color="red">wave_2</font> <font color="red">reflections_2</font> <font color="red">[_2</font> <font color="red">pulse_2</font> <font color="red">wave_2</font> <font color="red">velocity_2</font> <font color="red">(_2</font> <font color="red">PWV_2</font> <font color="red">)_2</font> <font color="red">and_1</font> <font color="red">augmentation_2</font> <font color="red">index_2</font> <font color="red">(_2</font> <font color="red">AI_2</font> <font color="red">)_2</font> <font color="red">application_2</font> <font color="red">tonometry_2</font> <font color="red">]_2</font> <font color="red">and_1</font> <font color="red">cardiac_2</font> <font color="red">echocardiography_2</font> <font color="red">._2</font> Periodically recorded were <font color="red">body_5</font> <font color="red">weight_5</font> <font color="red">,_5</font> <font color="red">BP_5</font> <font color="red">(_5</font> <font color="red">mercury_5</font> <font color="red">sphygmomanometer_5</font> <font color="red">)_5</font> <font color="red">,_5</font> <font color="red">serum_5</font> <font color="red">creatinine_5</font> <font color="red">,_5</font> <font color="red">electrolytes_5</font> <font color="red">,_5</font> <font color="red">complete_5</font> <font color="red">blood_5</font> <font color="red">cell_5</font> <font color="red">counts_5</font> <font color="red">,_5</font> <font color="red">urine_5</font> <font color="red">volume_5</font> <font color="red">,_5</font> <font color="red">drainage_5</font> <font color="red">volume_5</font> <font color="red">,_5</font> <font color="red">and_4</font> <font color="red">weekly_5</font> <font color="red">creatinine_5</font> <font color="red">clearance_5</font> <font color="red">._5</font> Two - way analysis of <font color="red">variance_1</font> <font color="red">for_1</font> <font color="red">repeated_1</font> <font color="red">measurements_2</font> was used for statistical analysis . <font color="red">Systolic_4</font> <font color="red">and_4</font> <font color="red">diastolic_4</font> <font color="red">BP_4</font> were both <font color="red">reduced_1</font> in patients treated with ARB . The <font color="red">LVMi_4</font> <font color="red">was_1</font> <font color="red">significantly_1</font> <font color="red">reduced_1</font> in patients treated with <font color="red">ARB_1</font> <font color="red">(_1</font> <font color="red">to_1</font> <font color="red">121_1</font> <font color="red">+_1</font> <font color="red">/-_1</font> <font color="red">4_1</font> <font color="red">from_1</font> <font color="red">145_1</font> <font color="red">+_1</font> <font color="red">/-_1</font> <font color="red">5_1</font> <font color="red">)_1</font> but not in those receiving placebo ( to 137 + /- 3 from 152 + /- 3 , p < 0.05 ) . The decrease in <font color="red">LVMi_3</font> was associated with a <font color="red">reduction_1</font> <font color="red">in_1</font> <font color="red">PWV_2</font> <font color="red">and_2</font> <font color="red">AI_2</font> <font color="red">._1</font> In CAPD patients with LVH , <font color="red">ARB_1</font> <font color="red">reduced_1</font> <font color="red">LVMi_3</font> <font color="red">in_1</font> <font color="red">association_1</font> <font color="red">with_1</font> <font color="red">alterations_1</font> <font color="red">in_1</font> <font color="red">arterial_2</font> <font color="red">hemodynamics_2</font> <font color="red">._2</font>